Atlanticus Holdings Corporation (ATLC)
NASDAQ: ATLC · Real-Time Price · USD
56.81
+7.20 (14.51%)
At close: Aug 8, 2025, 4:00 PM
56.82
+0.01 (0.02%)
After-hours: Aug 8, 2025, 4:10 PM EDT
Elevation Oncology Stock Forecast
Stock Price Forecast
The 6 analysts that cover Elevation Oncology stock have a consensus rating of "Buy" and an average price target of $64.17, which forecasts a 12.96% increase in the stock price over the next year. The lowest target is $54 and the highest is $75.
Price Target: $64.17 (+12.96%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Elevation Oncology stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Maintains $72 → $75 | Buy | Maintains | $72 → $75 | +32.02% | Jul 17, 2025 |
| Keefe, Bruyette & Woods | Keefe, Bruyette & Woods | Hold Reiterates $52 → $60 | Hold | Reiterates | $52 → $60 | +5.62% | May 12, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Maintains $75 → $72 | Buy | Maintains | $75 → $72 | +26.74% | Mar 21, 2025 |
| Keefe, Bruyette & Woods | Keefe, Bruyette & Woods | Hold Reiterates $45 → $52 | Hold | Reiterates | $45 → $52 | -8.47% | Mar 17, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $75 | Buy | Reiterates | $75 | +32.02% | Mar 14, 2025 |
Financial Forecast
Revenue This Year
1.50B
from 399.94M
Increased by 274.30%
Revenue Next Year
1.69B
from 1.50B
Increased by 12.69%
EPS This Year
5.98
from 4.77
Increased by 25.34%
EPS Next Year
7.85
from 5.98
Increased by 31.09%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 1.6B | 1.9B | 2.3B |
| Avg | 1.5B | 1.7B | 2.2B |
| Low | 1.4B | 1.5B | 2.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 296.8% | 25.8% | 35.5% |
| Avg | 274.3% | 12.7% | 31.7% |
| Low | 245.8% | -1.6% | 26.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 6.66 | 8.84 | 12.23 |
| Avg | 5.98 | 7.85 | 11.88 |
| Low | 5.05 | 7.06 | 11.42 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 39.4% | 47.7% | 55.9% |
| Avg | 25.3% | 31.1% | 51.5% |
| Low | 5.7% | 17.9% | 45.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.